Wedbush Securities Inc. Sells 884 Shares of iShares Biotechnology ETF $IBB

Wedbush Securities Inc. cut its holdings in iShares Biotechnology ETF (NASDAQ:IBB) by 27.5% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 2,327 shares of the financial services provider’s stock after selling 884 shares during the period. Wedbush Securities Inc.’s holdings in iShares Biotechnology ETF were worth $294,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the business. Ramirez Asset Management Inc. acquired a new position in iShares Biotechnology ETF during the 1st quarter valued at about $26,000. Berkshire Money Management Inc. purchased a new position in shares of iShares Biotechnology ETF during the second quarter valued at approximately $28,000. Harbor Asset Planning Inc. bought a new stake in iShares Biotechnology ETF during the second quarter worth $31,000. Trust Co. of Toledo NA OH purchased a new stake in iShares Biotechnology ETF in the 2nd quarter valued at $32,000. Finally, Security National Bank bought a new position in iShares Biotechnology ETF during the 2nd quarter valued at $38,000. Institutional investors and hedge funds own 62.45% of the company’s stock.

iShares Biotechnology ETF Trading Up 0.4%

NASDAQ IBB opened at $165.63 on Thursday. The company has a fifty day moving average price of $150.12 and a 200-day moving average price of $136.49. iShares Biotechnology ETF has a 1 year low of $107.43 and a 1 year high of $165.81.

iShares Biotechnology ETF Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, September 19th. Stockholders of record on Tuesday, September 16th were given a dividend of $0.0828 per share. The ex-dividend date was Tuesday, September 16th. This represents a $0.33 annualized dividend and a dividend yield of 0.2%.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.